Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Patient selection for trials.

Jerry S Wolinsky1

  • 1Department of Neurology, McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth), Houston, TX, USA.

Multiple Sclerosis (Houndmills, Basingstoke, England)
|October 19, 2017
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease (ORATORIO-HAND): a multicentre, double-blind, randomised, placebo-controlled, phase 3b study.

Lancet (London, England)·2026
Same author

Depression Polygenicity and Disease Activity and Disability Worsening in Multiple Sclerosis.

Annals of neurology·2025
Same author

Short- and long-term effects of early versus delayed treatment with ocrelizumab on cerebellar volume loss in patients with RMS and PPMS.

Multiple sclerosis (Houndmills, Basingstoke, England)·2025
Same author

Ethnoracial disparities in gray matter atrophy are mediated by structural disconnectivity in multiple sclerosis.

Annals of clinical and translational neurology·2025
Same author

Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials.

The Lancet. Neurology·2024
Same author

Detection of diffusely abnormal white matter in multiple sclerosis on multiparametric brain MRI using semi-supervised deep learning.

Scientific reports·2024
Same journal

Impact of multiple sclerosis disease-modifying therapies on chronic lesion tissue expansion.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Tobacco smoking disrupts bile acid and tryptophan metabolism in multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Missed radiologic disease activity by conventional side-by-side MRI comparison is associated with future disease activity in multiple sclerosis: Adopting semiautomated coregistration-fusion into clinical practice.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Longitudinal magnetic resonance spectroscopy study of metabolite changes over 2 years in relapsing and primary progressive multiple sclerosis treated with ocrelizumab.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Racial identity, marginalization, and depression in pediatric-onset multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Disability and race in MS: Does socioeconomic disadvantage play a role?

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
See all related articles

Progress in treating relapsing multiple sclerosis (MS) has advanced, and now research is accelerating for progressive MS. This review examines factors for successful primary progressive MS clinical trials and remaining challenges.

Area of Science:

  • Neurology
  • Neuroimmunology
  • Clinical Trials

Background:

  • Significant advancements have been made in understanding and treating relapsing forms of multiple sclerosis (MS).
  • Progress in treating progressive forms of MS has historically lagged but is now showing acceleration.
  • Primary progressive multiple sclerosis (PPMS) presents unique challenges for research and therapeutic development.

Purpose of the Study:

  • To review characteristics of patients with primary progressive multiple sclerosis (PPMS) relevant to phase 3 trial success.
  • To identify and discuss challenges in designing and conducting clinical trials for PPMS.
  • To explore implications for testing neuroprotective and repair therapeutics in progressive MS.

Main Methods:

  • Review of recent clinical trial data and methodologies in progressive multiple sclerosis.
Keywords:
Trial designefficacyoutcomes researchphenotypesprimary progressive multiple sclerosisprogression

Related Experiment Videos

  • Analysis of patient characteristics influencing trial outcomes in PPMS.
  • Discussion of challenges in trial design, participant selection, and outcome measures for PPMS studies.

    • Main Results:

    • Larger clinical trials have improved understanding of "pure" primary progressive disease.
    • Current trial designs and participant selection criteria require re-evaluation for future PPMS investigations.
    • Progress in therapeutic development for PPMS is gaining momentum.

    Conclusions:

    • Understanding PPMS patient characteristics is crucial for optimizing phase 3 trial success.
    • Innovative trial designs and participant selection are needed to advance PPMS research.
    • Future therapeutic strategies targeting neuroprotection and repair must consider ongoing disease progression in PPMS.